Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 874

Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Abstract Number: 875

Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial

Abstract Number: 876

Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling

Abstract Number: 877

Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis

Abstract Number: 878

Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis

Abstract Number: 879

Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.